Murray N, Badínez L, Badínez O, Orellana N, Dueñas R, Reyes E, Fuentealba C

Language: Spanish
References: 12
Page: 92-96
PDF size: 242.15 Kb.

ABSTRACT

Objective: To determine CD82, a metastasis inhibitor, expression in circulating prostate cells (CPCs) in blood before and after definitive treatment, its association with clinical parameters and the presence of bone micrometastasis.
Methods and patients: A cross-sectional multicentric study of consecutive prostate cancer patients attended to within the time frame of 2008 and 2009. Mononuclear cells were isolated from 8 mL of venous blood by differential centrifuge and CPCs were detected with anti- prostate specific antigen (PSA) and identified with immunocytochemistry. Positive samples were subclassified with anti-CD82. Details of stage, age and serum PSA level were registered. A bone marrow biopsy sample was processed in the same manner.
Results: A total of 105 patients participated; 30 pretreatment and 75 posttreatment. There was an association between CPC detection frequency, clinical stage and Gleason score. CD82 expression was associated with a low Gleason score and the absence of bone metastasis.
Conclusions: CD82 expression in CPCs is associated with low grade tumor and does not inhibit cancerous cell dissemination but it inhibits its implantation in bone marrow and is associated with local non-bone recurrence.

REFERENCES

1. Murray NP. El uso de doble-inmunomarcación para detectar células prostáticas en la circulación sanguínea (CPCs) en pacientes con cáncer prostático y las correlaciones con los parámetros clínicos. Rev Chil Urol 2006;71(2):135-140.

2. Cher ML, De Oliveira JG, Beaman AA. Cellular proliferation and prevalence of micrometastatic cells in the bone marrow of patients with clinically localized prostate cancer. Clin Cancer Res 1999;5(9):2421-2425.

3. Oberneder R, Riesenberg R, Kriegmair M. Immunocytochemical detection and phenotypic characterization of micrometastatic tumor cells in bone marrow of patients with prostate cancer. Uro Res 1994;22(1):3-8.

4. Wood DP Jr, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease free survival. J Clin Oncol 1997;15(12):3451-3457.

5. Kauffman EC, Robinson VL, Stadler WM. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cell growth at the secondary site. J Urol 2003;169(3):1122-1133

6. Robinson VL, Kaufmann EC, Sokoloff MH. The basic biology of metastasis. Cancer Treat Res 2004;118:1-21.

7. Shevede LA, Welch DR. Metastasis suppressor pathways: an evolving paradigm. Cancer Lett 2003;198(1):1-20.

8. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2000;2(28):563-572.

9. Dong JT, Suzuki H, Pin SS. Down regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996;56(19):4387-4390.

10. Lijovic M, Somers G, Frauman AG. KAI1/CD82 protein expression in primary prostate cancer and in BPH associated with cancer. Cancer Detect Prev 2002;26(1):69-77.

11. Jackson P, Ow K, Yardley G. Downregulation of KAI1 mRNA in localized prostate cancer and its bony metastases does not correlate with p53 over expression. Prostate Cancer Prostatic Dis 2003;6(2):174-181.

12. Borgen E. Standardization of the immunocytochemical detection of cancer cells in BM and blood: Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999;5(1):377-388.